Turnstone Biologics
A clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy.
The company's TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TILs that have demonstrated objective responses only in limited tumor types.
Turnstone's lead program, TIDAL-01, is being evaluated in two Phase I studies as of Q3 2023 in patients with melanoma, breast cancer, and colorectal cancer. It is also actively advancing a pipeline of preclinical programs, including TIDAL-02.
Latest Turnstone Biologics News & Features
24 July 2023
20 December 2019
16 November 2017
10 October 2017
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze